The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activation domain with properties different from those of VP16.
about
SKIP, a CBF1-associated protein, interacts with the ankyrin repeat domain of NotchIC To facilitate NotchIC functionTargeting of the visna virus tat protein to AP-1 sites: interactions with the bZIP domains of fos and jun in vitro and in vivo.A role for SKIP in EBNA2 activation of CBF1-repressed promotersEpstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodiesThe C-mer gene is induced by Epstein-Barr virus immediate-early protein BRLF1Pattern of aromatic and hydrophobic amino acids critical for one of two subdomains of the VP16 transcriptional activatorVisna virus Tat protein: a potent transcription factor with both activator and suppressor domainsN-terminal transcriptional activation domain of LZIP comprises two LxxLL motifs and the host cell factor-1 binding motifThe transcriptional activator GCN4 contains multiple activation domains that are critically dependent on hydrophobic amino acidsRepression and activation domains of RME1p structurally overlap, but differ in genetic requirements.A transcriptional activating region with two contrasting modes of protein interaction.A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus.Domains with transcriptional regulatory activity within the ALL1 and AF4 proteins involved in acute leukemia.Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinasesThe Epstein-Barr virus protein BRLF1 activates S phase entry through E2F1 induction.Origin-independent assembly of Kaposi's sarcoma-associated herpesvirus DNA replication compartments in transient cotransfection assays and association with the ORF-K8 protein and cellular PML.Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation.Epstein-Barr virus immediate-early protein BRLF1 interacts with CBP, promoting enhanced BRLF1 transactivation.DNA binding by Kaposi's sarcoma-associated herpesvirus lytic switch protein is necessary for transcriptional activation of two viral delayed early promoters.A replication function associated with the activation domain of the Epstein-Barr virus Zta transactivator.The herpesvirus saimiri ORF50 gene, encoding a transcriptional activator homologous to the Epstein-Barr virus R protein, is transcribed from two distinct promoters of different temporal phasesGenome-wide analysis of Epstein-Barr virus Rta DNA bindingDNA-dependent transregulation by IE1 of Autographa californica nuclear polyhedrosis virus: IE1 domains required for transactivation and DNA binding.Identification of seven hydrophobic clusters in GCN4 making redundant contributions to transcriptional activationExtensive mutagenesis of a transcriptional activation domain identifies single hydrophobic and acidic amino acids important for activation in vivoCharacterization of a bovine herpesvirus 4 immediate-early RNA encoding a homolog of the Epstein-Barr virus R transactivator.Transcriptional activation by the acidic domain of Vmw65 requires the integrity of the domain and involves additional determinants distinct from those necessary for TFIIB bindingEarly activation of the Kaposi's sarcoma-associated herpesvirus RTA, RAP, and MTA promoters by the tetradecanoyl phorbol acetate-induced AP1 pathway.Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression.Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism.The embryonic transcription factor stage specific activator protein contains a potent bipartite activation domain that interacts with several RNA polymerase II basal transcription factors.Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta.Epstein-Barr virus utilizes Ikaros in regulating its latent-lytic switch in B cells.Replication of Epstein-Barr virus oriLyt: lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays.EBNA-2 of herpesvirus papio diverges significantly from the type A and type B EBNA-2 proteins of Epstein-Barr virus but retains an efficient transactivation domain with a conserved hydrophobic motif.The Epstein-Barr virus immediate-early gene product, BRLF1, interacts with the retinoblastoma protein during the viral lytic cycle.The leucine domain of the visna virus Tat protein mediates targeting to an AP-1 site in the viral long terminal repeat.Essential role of Rta in lytic DNA replication of Epstein-Barr virusTranscriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells.The activation domain of herpesvirus saimiri R protein interacts with the TATA-binding protein.
P2860
Q22253329-56715F86-DABD-40B4-9A5D-AF4D45EA04C0Q24516921-08DB12ED-68AE-4A9D-AD81-3FCC932EEDC6Q24524363-EA2A3BBF-A7A7-4ACC-A7A7-34F448CF69E5Q24529499-438E0DDE-24E7-42CA-B3F5-88C7A9B70CF5Q24563120-1F9F45C5-022D-4183-808B-544EEB0B1FAFQ24563645-A081275B-E965-4687-AEAB-8E5547FCDD4CQ24645727-95F3F22B-C75E-4D12-90D7-ED4500E51EE4Q24649820-1F756BC0-7868-4DC8-9978-0FD788CD9890Q24652864-14587114-8CA6-48BD-A4C3-3ECB04CBAB37Q27931074-E70920CF-2DD6-418A-A600-D02A1C4A8A58Q27939457-4C2A7A55-5B16-43FF-AEB9-E9022B554B47Q33559699-ADCD2814-BF52-410D-A368-F02AC97C37B5Q33652400-C1E73F98-0ED1-4271-822F-B231170BF71BQ33793163-2FDF9384-D8C3-40EB-B007-CB65974813B7Q33817088-B27A1120-E356-49D9-A81E-96005986DE10Q33836726-D82DE58C-9425-4F84-8B97-AC7625C61889Q33842581-EC980A9C-4686-4E89-8182-C744691A0458Q33842700-2C972ACF-F5AF-4A5F-B68A-5AEF41DED15DQ33844093-88675F6A-967B-43E8-A508-A0250120B2BCQ35873179-17897A2F-25A3-42FE-A40E-E6FFFCE9CAC5Q35880026-B9A33A3E-0000-4A80-96EE-07AE575856C5Q35943838-E4A0D533-7269-4E97-8785-74A86FB9A7D8Q36548791-3D71AB6D-F845-4454-8242-7632A0BB5014Q36562751-ABBDE929-4CF6-4FE3-9F7C-22A6B71F2B4EQ36564643-FEE72654-72F0-4A65-BD90-68DD1D7AB274Q36640953-46E8EA19-E15B-4ACD-937B-DAFBB0E8F29BQ36698158-884E0F40-0025-4907-ABA4-B7CE97B510E2Q37093134-6DA5234F-EC90-449E-80F9-AD804B6FF013Q37093515-FC545E99-30B8-40D3-8EF7-39ECE9ECF6DEQ37389141-AEA88B3A-4DFB-45A9-8C68-10E221C31E5EQ37556094-B3E06A9F-4B03-40DD-9989-6702332D8921Q37596540-5B76154D-736B-49DF-B823-B608FB272F0CQ37713982-54738F8E-01A3-4915-9637-25A3D1AA3530Q38296033-9E69C4EF-8A7D-4591-98CE-A781D780C31EQ38318791-A412FB9D-63E6-415F-A0E0-9C0EF48604C9Q38333491-8B74C5B4-7AD4-46BC-A026-AE74C7A0F8B7Q38356073-D70C3AB4-E97C-4DE1-84D4-185905329671Q39257214-466E2CB1-23D8-40D1-BE88-6DB6E75974F9Q39596534-A0AF735A-2FD4-4317-9D77-3593895A4E93Q39596816-A5B2D686-5BF9-4CF5-90B2-D522405CB2B1
P2860
The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activation domain with properties different from those of VP16.
description
1992 nî lūn-bûn
@nan
1992 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
name
The Epstein-Barr virus R trans ...... different from those of VP16.
@ast
The Epstein-Barr virus R trans ...... different from those of VP16.
@en
type
label
The Epstein-Barr virus R trans ...... different from those of VP16.
@ast
The Epstein-Barr virus R trans ...... different from those of VP16.
@en
prefLabel
The Epstein-Barr virus R trans ...... different from those of VP16.
@ast
The Epstein-Barr virus R trans ...... different from those of VP16.
@en
P2093
P2860
P1433
P1476
The Epstein-Barr virus R trans ...... different from those of VP16.
@en
P2093
J M Hardwick
J Nicholas
M A Veliuona
N Applegren
P2860
P304
P407
P577
1992-09-01T00:00:00Z